Mylan Labs Makes A RecoveryBy
Although generic medicines remain the top choice among patients, the makers of these low-priced remedies have remained in the cellar: Investors have shied away because of price-cutting that seriously depressed earnings. But guess what? The price wars seem to be over, and certain generic-drug producers are sparking investors' interest.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.